Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
analysis
-
development of a fluorescence resonance energy transfer-based assay method as a rapid and reliable tool in future research for the identification and validation of potential SPase I inhibitors
drug development
-
type I signal peptidase is a potential target for the development of novel antibacterial agents
drug development
-
bacterial type I signal peptidase is a potential target for the development of antibacterial agents
drug development
-
in the search for antibacterial therapies, the type I signal peptidase serves as a potential target for development of antibacterials with another mode of action. SPase I is also is a feasible target for biofilm-associated infections
drug development
SPase I is a target for development of inhibitors as antibiotics
drug development
-
SPase I serves as a potentially interesting target for the development of antibacterials with another mode of action
drug development
-
bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors
drug development
-
bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors
drug development
bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
A0A1S0QR24
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
-
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
-
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
-
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
-
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
-
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
-
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
-
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
-
drug development
-
bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors
-
drug development
-
bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors
-
drug development
-
bacterial signal peptidase I (SPase) represents an attractive target in that SPase inhibitors exhibit broad-spectrum antibiotic activity, but even at sub-MIC doses also impair the secretion of essential virulence factors
-
drug development
-
bacterial signal peptidase I (SPase) is a target for development of beta-lactam anti-bacterial inhibitors
-
medicine
-
developing of medication designed to arrest tissue damage during Pseudomonas infection, opportunistic pathogen causes morbidity and mortality in patients with burns, cystic fibrosis, pneumonia, urinary tract infections, skin infections, cancer, acquired immunodeficiency syndrome, and ocular disease
medicine
-
inhibition of enzyme by arylomycin A-C16 results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity of cells when combined with an aminoglycoside. Antibiotics tetracycline, erythromycin, and vancomycin each interact additively with arylomycin A-C16, while rifampin and trimethoprim show pronounced antagonism
medicine
-
inhibition of enzyme by arylomycin A-C16 results in an insufficient flux of proteins through the secretion pathway leading to mislocalization of proteins. Inhibition results in synergistic sensitivity of cells when combined with an aminoglycoside. No significant interactions are observed between arylomycin A-C16 and erythromycin, polymyxin B, trimethoprim, or ciprofloxacin. Arylomycin A-C16 shows mild synergism with cephalexin, pronounced synergism with rifampin and gentamicin, and antagonism with the translational inhibitor tetracycline
medicine
-
developing of medication designed to arrest tissue damage during Pseudomonas infection, opportunistic pathogen causes morbidity and mortality in patients with burns, cystic fibrosis, pneumonia, urinary tract infections, skin infections, cancer, acquired immunodeficiency syndrome, and ocular disease
-
pharmacology
-
enzyme is essential for bacterial cell viability, potential molecular target for development of novel antibacterial agents
pharmacology
possible targets for the design of novel antibiotics
pharmacology
possible targets for the design of novel antibiotics
pharmacology
-
signal peptidase structure will be useful in the design of new and improved inhibitors which may be of pharmaceutical importance
pharmacology
-
signal peptidase structure will be useful in the design of new and improved inhibitors which may be of pharmaceutical importance
pharmacology
-
the gram positive pathogen plays a significant role in infectious disease, including life threatening methicillin-resistant MRSA infections, the ability to screen for inhibitors of SpsB will represent a significant advance for discovery of antibacterial agents